

1 **MicroRNA-deficient embryonic stem cells**
2 **acquire a functional Interferon response**

3

4

5 **Jeroen Witteveldt, Lisanne Knol and Sara Macias***

6

7 Institute of Immunology and Infection Research, School of Biological Sciences,

8 University of Edinburgh, Edinburgh, EH9 3FL, UK

9 * Correspondence should be addressed to S.M (sara.maciasribela@ed.ac.uk)

10

11

12

13

14

15

16

17

18

19

20

21 **When mammalian cells detect a viral infection, they initiate a type-I Interferon (IFNs)**
22 **response as part of their innate immune system. This antiviral mechanism is conserved**
23 **in virtually all cell types, except for embryonic stem cells (ESCs) and oocytes which are**
24 **intrinsically incapable of producing IFNs. Despite the importance of the IFN response to**
25 **fight viral infections, the mechanisms regulating this pathway during pluripotency are**
26 **still unknown. Here we show that, in the absence of miRNAs, ESCs acquire an active IFN**
27 **response. Proteomic analysis identified MAVS, a central component of the IFN pathway,**
28 **to be actively silenced by miRNAs and responsible for suppressing IFN expression in**
29 **ESCs. Furthermore, we show that knocking out a single miRNA, miR-673, restores the**
30 **antiviral response in ESCs through MAVS regulation. Our findings suggest that the**
31 **interaction between miR-673 and MAVS acts as a switch to suppress the antiviral IFN**
32 **during pluripotency and present genetic approaches to enhance their antiviral immunity.**

33

34

35

36

37

38

39

40

41

42

43 **Introduction**

44 Type-I Interferons (IFN) are crucial cytokines of the innate antiviral response. Although
45 showing great variation, most mammalian cell types are capable of synthesizing type-I IFNs in
46 response to invading viruses and other pathogens. Once type-I IFNs are secreted, they activate
47 the JAK-STAT pathway and production of Interferon-stimulated genes (ISGs) in both the
48 infected and neighbouring cells to induce an antiviral state (Ivashkiv and Donlin, 2015). Two
49 major signalling pathways are involved in IFN production in the context of viral infections.
50 The dsRNA sensors RIG-I and MDA5 initiate a signalling cascade that signals through the
51 central mitochondrial-associated factor MAVS, ultimately activating *Ifnb-1* transcription. The
52 cGAS/STING pathway is activated upon detection of viral or other foreign DNA molecules
53 and uses a distinct signalling pathway involving the endoplasmic reticulum associated STING
54 protein (Chan and Gack, 2016).

55 Despite its crucial function in fighting pathogens, pluripotent mammalian cells do not exhibit
56 an interferon response. Both mouse and human embryonic stem cells (ESCs) (Wang *et al.*,
57 2013, Chen *et al.*, 2012) as well as embryonic carcinoma cells (Burke, Graham and Lehman,
58 1978) fail to produce IFNs, suggesting that this function is acquired during differentiation. The
59 rationale for silencing this response is not fully understood but it has been proposed that in their
60 natural setting, ESCs are protected from viral infections by the trophoblast, which forms the
61 outer layer of the blastocyst (Delorme-Axford, Sadovsky and Coyne, 2014). ESCs exhibit a
62 mild response to exogenous interferons, suggesting that during embryonic development,
63 maternal interferon could have protective properties (Hong and Carmichael, 2013, Wang *et al.*,
64 2014). In mouse ESCs, a Dicer-dependent RNA interference (RNAi) mechanism, reminiscent
65 to that of plants and insects, is suggested to function as an alternative antiviral mechanism
66 (Maillard *et al.*, 2013). And in humans, ESCs intrinsically express high levels of a subgroup of
67 ISGs in the absence of infection, bypassing the need for an antiviral IFN response (Wu *et al.*,

68 2018, Wu *et al.*, 2012). All these suggest that different antiviral pathways are employed
69 depending on the differentiation status of the cell. Silencing of the IFN response during
70 pluripotency may also be essential to avoid aberrant IFN production in response to
71 retrotransposons and endogenous retroviral derived dsRNA, which are highly expressed during
72 the early stages of embryonic development and oocytes (Ahmad *et al.*, 2018, Grow *et al.*, 2015,
73 Macia, Blanco-Jimenez and García-Pérez, 2015, Peaston *et al.*, 2004, Macfarlan *et al.*, 2012).
74 Furthermore, exposing cells to exogenous IFN induces differentiation and an anti-proliferative
75 state, which would have catastrophic consequences during very early embryonic development
76 (Borden, Hogan and Voelkel, 1982, Hertzog, Hwang and Kola, 1994).

77 All these observations support a model in which cells gain the ability to produce IFNs during
78 differentiation. One particular class of regulatory factors that are essential for the successful
79 differentiation of ESCs are miRNAs (Greve, Judson and Belloch, 2013). These type of small
80 RNAs originate from long precursor RNA molecules, which undergo two consecutive
81 processing steps, one in the nucleus by the Microprocessor complex, followed by a DICER-
82 mediated processing in the cytoplasm (Treiber, Treiber and Meister, 2018). The
83 Microprocessor complex is composed of the dsRNA binding protein DGCR8 and the RNase
84 III DROSHA which are both essential for mature miRNA production (Gregory *et al.*, 2004,
85 Lee *et al.*, 2003). In addition, mammalian DICER is also essential for production of siRNAs
86 (Bernstein *et al.*, 2001). The genetic ablation of *Dgcr8* or *Dicer* in mice blocks ESCs
87 differentiation suggesting that miRNAs are an essential factor for this, as these are the common
88 substrates for the two RNA processing factors (Wang *et al.*, 2007, Kanellopoulou *et al.*, 2005).

89 In this study, we show that miRNAs are responsible for suppressing the IFN response during
90 pluripotency, specifically to immunostimulatory RNAs. We found that miRNA-deficient ESCs
91 acquire an IFN-proficient state, are able to synthesize IFN- β and mount a functional antiviral
92 response. Our results show that miRNAs specifically downregulate MAVS (mitochondrial

93 antiviral signalling protein), an essential and central protein in the interferon response pathway.
94 In agreement, ESCs with increased MAVS expression or knock-out of the MAVS-regulating
95 miRNA miR-673, resulted in an increased IFN production and antiviral response. Our results
96 support a model where the MAVS-miR-673 interaction acts as a switch to suppress the IFN
97 response and consequently virus susceptibility during pluripotency.

98 **Results**

99 **ESCs fail to express IFN- β in response to viral DNA/RNA**

100 There are two major pathways for sensing intracellular viral infections and consequent
101 activation of the IFN response in cells. One senses dsRNA, usually originating from RNA
102 viruses, with MAVS as a central factor, and the second senses dsDNA, from DNA- and
103 retroviruses signalling through STING (McFadden, Gokhale and Horner, 2017). It has been
104 shown that mouse ESCs do not produce type-I IFNs in response to poly(I:C) transfection, a
105 synthetic analogue of dsRNA classically used to mimic viral RNA replication intermediates
106 (Wang *et al.*, 2013). In contrast, it is still unknown how mouse ESCs respond to
107 immunostimulatory DNA. To study this, two different mouse ESC cell lines (ESC1 and ESC2)
108 were transfected with poly(I:C) and G₃-YSD, an HIV-derived DNA that stimulates the
109 cGAS/STING pathway (Herzner *et al.*, 2015). As controls, NIH3T3 fibroblasts and BV-2
110 microglial cells were included. As expected, the transfection of poly(I:C) did not result in *Ifnb1*
111 expression in both ESC lines (**Figure 1A**). ESCs also failed to activate *Ifnb1* expression upon
112 G₃-YSD transfection, suggesting that the cGAS/STING pathway was also inactive (**Figure**
113 **1B**). Similarly, NIH3T3 cells, which have also been previously shown to have a defect in this
114 specific pathway (Cheng *et al.*, 2018), did not express *Ifnb1* in response to G₃-YSD (**Figure**
115 **1B**). These same cell lines were infected with the (+) ssRNA virus TMEV (Theiler's Murine
116 Encephalomyelitis Virus) and showed that ESCs are at least 30 times more sensitive than

117 NIH3T3 and BV-2 cells, which correlates with the ability of these cell lines to induce
118 *Ifnb1* mRNA expression (**Figure 1C**).

119 The ability of cells to express IFN in response to viruses or immunogenic nucleic acids is
120 assumed to be acquired during differentiation. To test this model, we *in vitro* differentiated
121 both ESC lines with retinoic acid and determined their ability to respond to poly(I:C). Briefly,
122 embryoid bodies were generated by a hanging droplet method for 48 hours before being
123 cultured in the presence of retinoic acid for 2 or 10 days. Samples from each of these time
124 points were analysed for expression of pluripotency and differentiation markers. The
125 pluripotency markers *Nanog* and *Pou5f1* (*Oct-4*) showed a rapid decrease in mRNA expression
126 during differentiation in both the cell lines (**Suppl. Figure 1A**), whereas differentiation
127 markers *Neurog2*, *Gata-6* and *Gata-4* showed a gradual increase (**Suppl. Figure 1B**)
128 confirming successful differentiation of the ESCs. Next, we compared the ability of ESCs (day
129 0) and retinoic-acid differentiated cells after 10 days (day 10) to express *Ifnb1* mRNA in
130 response to poly(I:C), and confirmed that differentiated cells acquired the ability to synthesize
131 *Ifnb1* to similar levels to the positive control cell line, BV-2 (**Figure 1D**).

132 **Dicer-deficient ESCs acquire an active IFN response**

133 Given the relevance of RNAi as an antiviral mechanism in mouse ESCs (Maillard *et al.*, 2013),
134 we next asked if ESCs, in the absence of the central factor for RNAi, Dicer, would be more
135 susceptible to RNA viruses. Unexpectedly, *Dicer*^{-/-} ESCs were more resistant to viruses
136 compared to their wild-type counterparts (previously named ESC2) (**Figure 2A**). Similar
137 results were obtained using the (-) ssRNA virus, Influenza A (IAV) (**Figure 2B**). Importantly,
138 mammalian Dicer has a dual function, being essential for both siRNA and miRNA biogenesis.
139 To determine whether these differences in viral susceptibility were due to the activity of Dicer
140 on siRNA or miRNA production, we compared *Dicer*^{-/-} cells with ESCs lacking the essential

141 nuclear factor for miRNA biogenesis, *Dgcr8*. The absence of *Dgcr8* also decreased TMEV and
142 IAV viral susceptibility, suggesting that miRNAs are responsible for suppressing the antiviral
143 response in ESCs (**Figure 2A-B**). Interestingly, *Dgcr8*^{-/-} cells were more resistant to virus
144 infection than *Dicer*^{-/-} cells, which supports a dual function for Dicer by also acting as a direct
145 antiviral factor targeting viral transcripts for degradation by RNAi. To rule out the possibility
146 of morphological differences influencing viral susceptibility, we performed a virus binding and
147 entry assay which showed no differences (**Suppl. Figure 2**).

148 Even though ESCs lack an IFN response (**Figure 1**), we wondered whether the differential
149 resistance to viral infections were the result of abnormal IFN activation due to the absence of
150 miRNAs. To test this hypothesis, we transfected the dsRNA analogue, poly(I:C) and G₃-YSD
151 in *Dgcr8* or *Dicer* deficient mESCs, and quantified *Ifnb1* expression by RT-qPCR. ESCs
152 lacking miRNAs (*Dgcr8*^{-/-} or *Dicer*^{-/-}) were able to respond to the dsRNA analog, poly(I:C)
153 and express *Ifnb1* in a dose dependent manner (**Figure 2C-D and Suppl. Figure 3A-B**),
154 whereas no significant response was observed with immunostimulatory DNA (**Figure 2C-D**).
155 These results show there is a correlation between viral susceptibility and the ability of miRNA-
156 deficient ESCs to express *Ifnb1*, and that miRNAs are responsible for silencing the IFN
157 response to dsRNA. To verify that the observed results are solely due to the absence of
158 miRNAs, we rescued the knockout cell lines by reintroducing *Dgcr8* and *Dicer* and observed
159 that these reverted to wild-type viral replication and susceptibility levels (**Figure 2E-F and**
160 **Suppl. Fig. 3C**). As a control, we confirmed rescue of miRNA production by Northern blot
161 (**Figure 2E-F**).

162 **miRNAs suppress MAVS expression in ESCs**

163 To understand where the IFN pathway is silenced in ESCs we blocked the interferon response
164 at defined points in the pathway and measured viral susceptibility. The inhibitor BX795 blocks

165 TBK1/IKK ϵ phosphorylation and consequently IRF3 transcriptional activity, whereas
166 BMS345541 is an inhibitor of the catalytic subunits of IKK and thus blocks Nf- κ B-driven
167 transcription. Both transcription factors are essential for the expression of *Ifnb1* and other pro-
168 inflammatory cytokines and initiation of an antiviral response (Lawrence, 2009, Schafer *et al.*,
169 1998). Both inhibitors increased viral susceptibility in wild type cells lines, however, the effect
170 was far greater in the knock out cell lines (**Figure 3A** and **Suppl. Figure 4A**), suggesting that
171 miRNAs regulate the interferon pathway upstream *Ifnb1* transcription.

172 We next aimed to identify, in an unbiased manner, differentially expressed proteins involved
173 in viral susceptibility in the presence or absence of miRNAs. To this end, the total proteome of
174 *Dgcr8*^{-/-} and the rescued cell line was analysed by mass spec analysis. STRING analyses of the
175 expression profiles revealed significant differences in a number of pathways, including
176 ribosome structure/function, mitochondrial activity and the oxidative phosphorylation
177 pathway, which were downregulated in the absence of miRNAs (**Figure 3B**, for complete list
178 see **Suppl. Excel file**). Measurement of Rhodamine 123 uptake in mitochondria, as an indirect
179 measure for oxidative phosphorylation activity (Scaduto and Grotyohann, 1999), confirmed
180 lower oxidative phosphorylation activity in the absence of miRNAs (*Dgcr8*^{-/-} and *Dicer*^{-/-})
181 (**Suppl. Figure 4B**). A search for differentially expressed proteins involved in the IFN response
182 did not reveal any significant changes except for the Mitochondrial antiviral-signalling protein
183 (MAVS), which in contrast to many other mitochondria-related proteins, was upregulated in
184 the absence of miRNAs. This protein has a central role in the RLR-induced (Rig-I-like
185 receptors) interferon pathway, where activated MDA5 and RIG-I receptors translocate to the
186 mitochondria and bind MAVS to ultimately induce *Ifnb1* expression (Kawai *et al.*, 2005).
187 Western blot and qRT-PCR analysis confirmed that MAVS was the only factor consistently
188 expressed to higher levels in both miRNA-deficient cell lines, *Dgcr8*^{-/-} and *Dicer*^{-/-} (**Figure 3C**,

189 lanes 2 and 5, and **Suppl. Figure 4C**), compared to a panel of other components of the same
190 innate immune response pathway (**Suppl. Figure 4D**).

191 **MAVS acts as a switch for IFN expression**

192 To confirm the involvement of miRNAs on MAVS expression, a dual luciferase assay system
193 was used where the 3'UTRs of MAVS, MDA5 and RIG-I were fused to a luciferase reporter
194 gene to compare luciferase activity in wild-type and knock-out ESCs. Only the MAVS 3'UTR
195 showed relatively higher luciferase expression levels in the knock-out lines when compared to
196 the empty plasmid, suggesting that the 3'UTR of MAVS is strongly regulated by miRNAs in
197 ESCs (**Figure 4A**). For this reason, we decided to overexpress a miRNA-resistant isoform of
198 MAVS in wild-type ESCs and test if cells regain viral resistance similar to miRNA deficient
199 ESCs. A cell line overexpressing the ORF of MAVS, lacking its 3'UTR, was generated (**Figure**
200 **4B**) and infected with TMEV. A 15-fold decrease in TCID₅₀ and significant reduction in vRNA
201 levels were found when compared to wild-type ESCs (**Figure 4C**). MAVS overexpressing cells
202 also regained the ability to produce *Ifnb1* after stimulation with poly(I:C) (**Figure 4D**). All
203 these experiments show that MAVS is a crucial target for the downregulation of the IFN
204 response in ESCs.

205 **miR-673 is crucial to suppress antiviral immunity in ESCs**

206 We next aimed to identify the miRNA(s) responsible for the regulation of MAVS in ESCs and
207 selected a number of miRNA candidates based on literature, prediction software and public
208 miRNA expression databases for further investigations. Previous experimental evidence has
209 shown that human MAVS is regulated by miR-125a, miR-125b and miR-22 (Hsu *et al.*, 2017,
210 Wan *et al.*, 2016). However, only miR-125a-5p and miR-125b-5p have conserved binding sites
211 in mouse MAVS. Two additional miRNAs, miR-185-5p and miR-673-5p, were selected based
212 on their high expression levels in mouse ESCs and number of predicted binding sites in the

213 MAVS 3'UTR. We transfected *Dgcr8*^{-/-} cells with mimics of these miRNAs and measured
214 MAVS mRNA and protein levels by RT-qPCR and western blot, respectively. Results showed
215 reductions in MAVS protein and mRNA levels for all tested miRNAs (**Figure 5A** and **Suppl.**
216 **Fig. 5A**). The infection of miRNA-transfected *Dgcr8*^{-/-} cells with TMEV resulted in an increase
217 in both susceptibility and viral replication for miR-125a-5p, miR-125b-5p and miR-673-5p,
218 which correlated with the ability of these miRNAs to downregulate MAVS protein levels
219 (**Figure 5B** and **Suppl. Figure 5B**).

220 As an alternative approach, *Dgcr8*^{+/+} cells were transfected with inhibitors to miRNAs miR-
221 125a-5p, miR-125b-5p and miR-673-5p. Western blot analysis showed a clear increase in
222 MAVS protein expression, especially for anti-miR-673-5p (**Figure 5C**). Because miR-673-5p
223 showed the largest effect on MAVS protein expression both when depleted and overexpressed,
224 we hypothesize that miR-673 is a crucial miRNA involved on MAVS regulation.

225 We further investigated the role of miR-673-5p in ESCs by creating stable knock-out cell lines
226 for miR-673 by CRISPR/Cas9. Three cell lines were selected based on the genomic deletion
227 and confirmed undetectable expression of miR-673-5p (**Figure 5D** and **Suppl. Figure 6A**).
228 The absence of miR-673-5p was enough to observe an increase in MAVS expression both at
229 the mRNA and protein levels (**Figure 5E** and **Suppl. Figure 6B**). In addition, we measured
230 miR-673 and MAVS expression levels in the mouse fibroblasts cell line, NIH3T3, which is
231 proficient in producing IFN in response to dsRNA. Mouse fibroblasts had no detectable miR-
232 673-5p, and MAVS protein expression was comparable to miRNA-deficient ESC (**Figure 5D-**
233 **E**), highlighting the correlation of MAVS expression with the ability of cells to activate *Ifnb1*
234 expression in response to immunogenic RNA (**Figure 1**).

235 Next, miR-673 deficient cell lines were tested for TMEV susceptibility, which showed a
236 consistent decrease in virus replication, similar to that observed in the absence of all miRNAs

237 (*Dgcr8*^{-/-}), suggesting this miRNA is essential in regulating the innate antiviral response in
238 ESCs (**Figure 5F**).

239 Together these data show that the interferon response in mouse ESCs is actively suppressed by
240 the post-transcriptional regulation of MAVS expression by miR-673-5p.

241 **Discussion**

242 Several studies suggest that the pluripotent state of a cell is incompatible with an active
243 interferon response (Guo *et al.*, 2015). Both mouse and human stem cells fail to synthesize
244 interferons in response to dsRNA (Wang *et al.*, 2013, Chen, Yang and Carmichael, 2010),
245 implying that this characteristic is acquired during differentiation (D'Angelo *et al.*, 2016).
246 Embryonic carcinoma cells, which are still pluripotent, also fail to produce interferons in
247 response to viral RNA mimics (Burke, Graham and Lehman, 1978). In agreement,
248 reprogramming of somatic cells to iPSCs (induced pluripotent stem cells) leads to a loss of
249 interferon response, suggesting the presence of regulatory mechanisms able to switch this
250 antiviral pathway on or off between the differentiated and pluripotent states (Chen *et al.*, 2012).
251 Another feature of pluripotent cells is their attenuated response to exogenous type-I interferons.
252 Mammalian pluripotent stem cells, iPSCs and embryonic carcinoma cells exhibit an attenuated
253 production of interferon-stimulated genes upon type-I IFN stimulation (Hong and Carmichael,
254 2013, Irudayam *et al.*, 2015, Wang *et al.*, 2014, Burke, Graham and Lehman, 1978). Why
255 these activities are suppressed is still not understood, but it has been hypothesized that type-I
256 IFN stimulation could impair their self-renewal capacity, since these compounds are well-
257 known antiproliferative agents and inducers of cell death (Bekisz *et al.*, 2010). Indeed, type-I
258 IFNs are capable of inhibiting tumor cell division *in vitro* and are currently employed as an
259 adjuvant to treat several types of cancers, acting as stimulants of the innate immune cellular
260 response (Bracci *et al.*, 2017).

261 Mouse ESCs express low levels of the RNA sensors TLR3, MDA5 and RIG-I, which could
262 explain their inability to respond to dsRNA although no functional studies support this model
263 so far (Wang *et al.*, 2013). Our data shows an alternative scenario in which MAVS is the key
264 factor for controlling the IFN response. The overexpression of a miRNA-resistant form of
265 MAVS in wild-type ESCs is enough to enable dsRNA-mediated IFN activation, suggesting
266 that dsRNA sensing is not a limiting step in the IFN pathway in ESCs. Regulation of MAVS
267 alone proves to be an efficient mechanism to block dsRNA induced IFN expression compared
268 to suppressing individual dsRNA sensors.

269 The observation that miRNAs only suppress RNA-mediated IFN activation, but not the DNA-
270 mediated pathway, leads us to speculate about the reasons for silencing this specific response
271 during pluripotency. Embryonic stem cells, and also earlier stages of embryonic development
272 are characterized by high expression levels of specific retrotransposons (non-LTR) and
273 endogenous retroviruses (LTR), which are a hallmark of their pluripotent state. This is in
274 contrast to most somatic cell types that silence their expression (Yin, Zhou and Yuan, 2018).
275 These repetitive elements produce cytoplasmic RNA molecules as an intermediate for
276 mobilisation, which can be accidentally recognised as immunogenic or non-self RNAs, as it
277 has been previously shown for the human non-LTR retroelement Alu in the context of Aicardi-
278 Goutieres syndrome or for endogenous retroviruses (Ahmad *et al.*, 2018, Chiappinelli *et al.*,
279 2015, Roulois *et al.*, 2015). Therefore, silencing the RNA-mediated IFN response during
280 pluripotency would act as a protective mechanism for aberrant IFN activation by transposon-
281 derived transcripts.

282 Cells that are incapable of activating the RNA-mediated IFN response have developed
283 alternative antiviral defence pathways. The endonuclease Dicer can act as an antiviral factor in
284 mouse ESCs by generating antiviral siRNAs (Maillard *et al.* 2013). Detection of antiviral Dicer

285 activity is facilitated in the absence of a competent IFN response, such as in the case of
286 pluripotent cells, but also in somatic cells where the type-I IFN response has been genetically
287 impaired (Maillard *et al.*, 2016). These findings are supported by the observation that in IFN-
288 competent cells, the RNA sensor LGP2 acts as an inhibitor of Dicer cleavage activity on
289 dsRNA (van der Veen *et al.*, 2018). However, Dicer activity has also been reported in other
290 cell lines, independently of their IFN-proficiency capacity (Li *et al.*, 2016). Interestingly, when
291 we disrupt Dicer in ESCs, which inherently lack an IFN response and would theoretically
292 render these cells highly sensitive to viral infections, they become more resistant by acquiring
293 an active IFN response. All these results support the presence of extensive cross-talk between
294 the different antiviral strategies, and suggests that cells have developed mechanisms to
295 compensate for the loss of a specific antiviral pathway.

296 Our model shows that MAVS and miR-673 levels are the key factors regulating the IFN
297 response to dsRNAs during pluripotency. Accordingly, overexpressing MAVS or knocking-
298 out this single miRNA in ESCs is enough to enhance their antiviral response. Interestingly,
299 this miRNA is only conserved in rodents, despite human ESCs also suppressing type-I IFNs
300 expression (Hong and Carmichael, 2013). This suggests that either other miRNAs regulate
301 MAVS expression in human ESCs, or alternative mechanisms operate to silence IFN.
302 Interestingly, human ESCs constitutively express a subset of Interferon stimulated genes to
303 protect them from viruses (Wu, *et al.*, 2018), but whether miRNAs control the expression of
304 *Ifnb1* or this subset of ISGs in this context remains an unexplored matter.

305 Previous findings also support a general role for DICER and miRNAs acting as negative
306 regulators of the IFN response in human and mouse models outside pluripotency
307 (Papadopoulou *et al.*, 2012, Witteveldt, Ivens and Macias, 2018). In agreement, an indirect
308 approach to deplete cellular miRNAs, by overexpressing the viral protein VP55 from Vaccinia

309 virus, showed that miRNAs are also relevant to control the expression of pro-inflammatory
310 cytokines during viral chronic infections, but not in the acute antiviral response (Aguado *et al.*,
311 2015). However, the concept of miRNAs acting as direct antiviral factors is still controversial.
312 It is relevant to mention that some of the results leading to this conclusion have been primarily
313 generated in *Dicer*^{-/-} HEK293T human cell line (Bogerd *et al.*, 2014, Tsai *et al.*, 2018), which
314 has an attenuated IFN response due to low PRRs expression (Rice *et al.*, 2014, Witteveldt,
315 Ivens and Macias, 2018).

316 We have shown that overexpression of MAVS or silencing specific miRNAs in a transient or
317 stable manner improves the antiviral response of ESCs. These findings are the basis to further
318 study the conservation of the miRNA-mediated regulation of the IFN response in somatic cells
319 and in the context of human pluripotency. All these investigations will provide a deeper
320 understanding and tool set on how to enhance the innate immunity of ESCs and their
321 differentiated progeny, an especially relevant aspect in clinical applications.

322

323

324

325

326

327

328

329

330

331 **Methods**

332 **Cells and viruses**

333 *Dgcr8* knockout (*Dgcr8*^{-/-}) mouse ESCs were purchased from Novus Biologicals (NBA1-
334 19349) and the parental strain, v6.5 (*Dgcr8*^{+/+}, also named in the text ESC1) from
335 ThermoFisher (MES1402). *Dicer*^{flox/flox} (*Dicer*^{+/+}, also named ESC2) and *Dicer* knockout
336 (*Dicer*^{-/-}) mouse ESCs were provided by R. Belloch lab (University of California, San
337 Francisco). All mESC cells were cultured in Dulbecco's modified Eagle Medium (DMEM,
338 ThermoFisher) supplemented with 15% heat-inactivated foetal calf serum (ThermoFisher), 100
339 U/ml penicillin, 100 µg/ml streptomycin (ThermoFisher), 1X Minimal essential amino acids
340 (ThermoFisher), 2 mM L-glutamine, 10³ U/ml of LIF (Stemcell Technologies) and 50 µM 2-
341 mercaptoethanol (ThermoFisher). Cells were grown on plates coated with 0.1% Gelatine
342 (Embryomax, Millipore), detached using 0.05% Trypsin (ThermoFisher) and incubated at 5%
343 CO₂ at 37° C. MDCK, BHK-21, BV-2 and RAW264.7 cells were cultured in Dulbecco's
344 modified Eagle Medium (DMEM, ThermoFisher) supplemented with 10% heat-inactivated
345 foetal calf serum (ThermoFisher), 100 U/ml penicillin, 100 µg/ml streptomycin
346 (ThermoFisher), 2 mM L-glutamine and incubated at 5% CO₂ at 37° C. NIH3T3 cell line was
347 provided by A. Buck lab, and grown in DMEM supplemented with 10% FCS. Stocks of TMEV
348 strain GDVII were grown on BHK-21 cells and frozen in aliquots at -80°C. Stocks of Influenza
349 A virus strain PR8 (kindly provided by P. Digard, University of Edinburgh) were grown on
350 MDCK cells in the absence of serum and in the presence of 2 µg/ml TPCK-treated trypsin and
351 frozen in aliquots at -80°C.

352 For TMEV infections, cells were infected for 1 hour with the required dilution, followed by
353 replacement with fresh medium and incubation for the desired time. For the 50% Tissue Culture
354 Infective dose (TCID₅₀) assays, seven serial dilutions of TMEV were prepared and at least 6

355 wells (in 96-well format) per dilution were infected and incubated for at least 24 hours before
356 counting infected wells. TCID₅₀ values were calculated using the Spearman and Kärber
357 algorithm. Influenza A virus infections were performed by infecting cells in the absence of
358 serum for 45 minutes with the addition of 2 µg/ml TPCK-treated trypsin. After replacement of
359 the inoculum with fresh serum containing medium the cells were incubated for the desired
360 period.

361 **Differentiation of mESCs**

362 To differentiate mESCs, they were first cultured as hanging droplets to induce embryoid body
363 formation. For this, a single-cell suspension of 5x10⁵ cells/ml was prepared in medium without
364 LIF and 20 µl drops are pipetted on the inside of the lid of a 10 cm petri dish and hung upside-
365 down. The petri-dish was filled with PBS to prevent drying of the hanging drops and incubated
366 at 37°C, 5% CO₂ for 48 hours. The embryoid bodies were consequently washed from the lids
367 and transferred to petri dishes to further differentiate, all in the absence of LIF. After another
368 incubation time of 48hrs, medium was removed and replaced with fresh medium containing
369 250nM of retinoic acid (Sigma-Aldrich) and incubated for 7 days while replacing the medium
370 every 48 hours. After this incubation time, the embryoid bodies were collected and plated on
371 normal gelatine-coated cell culture plates which allowed the embryoid bodies to adhere to the
372 plastic and the cells to migrate from the embryoid bodies. Again, the medium was refreshed
373 every 48 hours for the cells to further differentiate.

374 **Northern blot for miRNAs**

375 Total RNA (15µg) was loaded on a 10% TBE-UREA gel. After electrophoresis, gel was stained
376 with SYBR gold for visualization of equal loading. Gel was transferred onto a positively
377 charged Nylon membrane for 1 hr at 250 mA. After UV-crosslinking, the membrane was pre-
378 hybridized for 4 h at 40°C in 1xSSC, 1%SDS (w/v) and 100mg/ml single-stranded DNA

379 (Sigma). Radioactively labelled probes corresponding to the highly expressed ESCs miRNAs
380 miR-130-3p, miR-293-3p, and miR-294-3p were synthesized using the mirVana miRNA Probe
381 Construction Kit (Ambion) and hybridized overnight in 1xSSC, 1%SDS (w/v) and 100mg/ml
382 ssDNA. After hybridization, membranes were washed four times at 40°C in 0.2xSSC and
383 0.2%SDS (w/v) for 30 min each. Blots were analysed using a PhosphorImager (Molecular
384 Dynamics) and ImageQuant TL software for quantification. Oligonucleotides used are listed
385 in Table S1.

386 **Transfections of Ppoly(I:C), DNA, miRNA mimics and Antagomirs**

387 To activate the IFN response, cells were transfected with either the dsRNA analogue poly(I:C)
388 (Invivogen) or the Y-shaped-DNA cGAS agonist (G3-YSD, Invivogen) using Lipofectamine
389 2000 (ThermoFisher). Transfections were performed in 24-well format, with cells
390 approximately 80% confluent, using different concentrations of poly(I:C), from 0,5 to 2,5 µg
391 per well (as indicated in the figures) or 0.5 µg of G3-YSD. Cells were incubated for
392 approximately 16 hours for poly(I:C)- and 8 hours for DNA-transfections before harvest and
393 further processing.

394 For the miRNA mimics (miScript, Qiagen) a final concentration of 1 µM was transfected into
395 cells using Dharmafect (Dharmacon), incubated for the desired period and further processed.
396 The same procedure was followed for the antagomirs (Dharmacon), but at a concentration of
397 100nM. All experiments were performed in 24-well format, with cells at approximately 80%
398 confluency.

399 **Quantitative RT-PCR**

400 Total RNA from cells was isolated using Tri reagent (Sigma-Aldrich) according to the
401 manufacturer's instructions. 0.5-1 µg RNA was subsequently reverse transcribed using M-
402 MLV (Promega) and random hexamers, and used for quantitative PCR in a StepOnePlus real-

403 time PCR machine (ThermoFisher) using GoTaq master mix (Promega). Data was analysed
404 using the StepOne software package. Oligonucleotides used are listed in **Table S1**.

405 **Cell lysis and Western Blots**

406 Cells used for Western blot analysis were lysed in RIPA buffer (50 mM TRIS-HCl, pH 7.4,
407 1% triton X-100, 0.5% Na-deoxycholate, 0.1% SDS, 150 mM NaCl, protease inhibitor cocktail
408 (Roche), 5mM NaF, 0.2 mM Sodium orthovanadate). Lysates were spun and protein
409 concentrations measured using a BCA protein assay kit (BioVision). After adjusting protein
410 concentrations, lysates were mixed with reducing agent (Novex, ThermoFisher) and LDS
411 sample buffer (Novex, ThermoFisher) and boiled at 70°C for 10 minutes before loading on pre-
412 made gels (NuPAGE, ThermoFisher). Proteins were transferred to nitrocellulose membrane
413 using semi-dry transfer (iBlot2, ThermoFisher). Membranes were blocked for 1 hour at room
414 temperature in PBS-T (0.1% Tween-20) and 5% milk powder before overnight incubation at
415 4°C with primary antibody. Antibodies used were: Anti-rabbit HRP (Cell Signaling
416 Technology), Anti-mouse HRP (Bio-Rad), MAVS (E-6, Santa Cruz Biotechnology), PKR
417 (ab45427, Abcam), MDA5 (D74E4, Cell Signaling Technology), RIG-I (D12G6, Cell
418 Signaling Technology) and α -tubulin (CP06, Merck). Proteins bands were visualised using
419 ECL (Pierce) on a Bio-Rad ChemiDoc imaging system. Protein bands were quantified using
420 ImageJ (v1.51p) software and expression levels calculated normalized to α -tubulin.

421 **Luciferase assay**

422 The 3'UTRs from MDA5, RIG-I and MAVS were amplified from genomic DNA based on the
423 annotation from UTRdb (utrdb.ba.itb.cnr.it) using primers containing restriction sites. The
424 fragments were cloned in the psiCHECK-2 vector (Promega) at the 3' end of the *hRluc* gene.
425 Cells in 24-well format were transfected with 250 ng plasmid using Lipofectamine 2000 and
426 incubated for 24 hours. Cells were subsequently lysed and assayed using the Dual-Glo

427 Luciferase assay system (Promega). Luminescence was measured in a Varioskan flash
428 (ThermoFisher) platereader.

429 **Proteomics**

430 For the total proteome comparison, 6 replicates of the *Dgcr8^{-/-}* and *Dgcr8^{resc}* cell lines were
431 prepared by lysing cells in Lysis buffer (50 mM TRIS-HCl, pH 7.4, 1% triton X-100, 0.5% Na-
432 deoxycholate, 0.1% SDS, 150 mM NaCl, protease inhibitor cocktail (Roche), 5mM NaF and
433 0.2 mM Sodium orthovanadate) at 4°C. Samples were subsequently sonicated 4x 10s, at 2μ
434 amplitude, reduced by boiling with 10 mM DTT and centrifuged. The samples were further
435 processed by Filter-aided sample preparation (FASP) by mixing each sample with 200 μl UA
436 (8M Urea, 0.1 M Tris/HCl pH 8.5) in a Vivacon 500 filter column (30 kDa cut off, Sartorius
437 VN01H22), centrifuged at 14.000 x g and washed twice with 200 μl UA. To alkylate the
438 sample, 100 μl 50 mM iodoacetamide in UA was applied to the columns and incubated in the
439 dark for 30 minutes, spun, followed by two washes with UA and another two washes with 50
440 mM ammonium bicarbonate. The samples were trypsinized on the column by the addition of
441 4 μg trypsin (ThermoFisher) in 40 μl 50 mM ammonium bicarbonate to the filter. Samples
442 were incubated overnight in a wet chamber at 37°C and acidified by the addition of 5 μl 10 %
443 trifluoroacetic acid (TFA). The pH was checked by spotting onto pH paper, and peptide
444 concentration estimated using a NanoDrop. C18 Stage tips were activated using 20 μl of
445 methanol, equilibrated with 100 μl 0.1% TFA) and loaded with 10 μg peptide solution. After
446 washing with 100uL 0.1% TFA, the bound peptides were eluted into a Protein LoBind 1.5mL
447 tube (Eppendorf) with 20μl 80% acetonitrile, 0.1% TFA and concentrated to less than 4 μl in
448 a vacuum concentrator. The final volume was adjusted to 6 μl with 0.1% TFA.

449 Five μg of peptides were injected onto a C18 packed emitter and eluted over a gradient of 2%-
450 80% ACN in 120 minutes, with 0.1% TFA throughout on a Dionex RSLnano. Eluting peptides

451 were ionised at +2kV before data-dependent analysis on a Thermo Q-Exactive Plus. MS1 was
452 acquired with m/z range 300-1650 and resolution 70,000, and top 12 ions were selected for
453 fragmentation with normalised collision energy of 26, and an exclusion window of 30
454 seconds. MS2 were collected with resolution 17,500. The AGC targets for MS1 and MS2
455 were 3e6 and 5e4 respectively, and all spectra were acquired with 1 microscan and without
456 lockmass. Finally, the data were analysed using MaxQuant (v 1.5.7.4) in conjunction with
457 uniprot fasta database 2017_02, with match between runs (MS/MS not required), LFQ with 1
458 peptide required. Average expression levels were calculated for each protein and significant
459 differences identified using a two tailed t-test assuming equal variance (homoscedasticity) with
460 a p-value lower than 0.05.

461 **Stable cell lines overexpressing DGCR8, Dicer and MAVS**

462 Plasmids containing the sequence of mouse Dicer (pCAGEN-SBP-DICER1, Addgene),
463 MAVS (GE-healthcare, MMM1013-202764911) and DGCR8 (Macias *et al.*, 2012) were used
464 to amplify the open reading frame using specific primers containing restriction sites (**Table**
465 **S1**). The amplified and digested fragments were ligated in pLenti-GIII-EF1 α for MAVS and
466 pEF1 α -IRES-dsRED-Express2 for DGCR8 and Dicer. Verified plasmids containing the genes
467 of interest were transfected in mESCs using Lipofectamine 2000 and selected with the
468 appropriate antibiotic. After several weeks of selection, colonies were isolated, expanded and
469 tested for expression by qRT-PCR and Western blot.

470 **Mitochondrial activity**

471 The mitochondria specific dye Rhodamine 123 (Sigma-Aldrich) was used to measure
472 mitochondrial activity. Suspended cells were incubated with Rhodamine 123 at 37°C and
473 samples were taken at various intervals, washed three times with PBS at 4°C and the

474 fluorescence measured in a VarioSkan flash (ThermoFisher) plate reader (excitation 508,
475 emission 535).

476 **Inhibitors**

477 Cells were pre-incubated with the inhibitors BX795, which blocks the phosphorylation of the
478 kinases TBK1 and IKK ϵ , and consequently IRF3 activation and IFN- β production (10 μ M,
479 Synkinase) and the inhibitor BMS345541, which targets IK β α , IKK α and IKK β and
480 consequently NF- κ β signalling (10 μ M, Cayman Chemical) for 45 minutes before infection
481 with TMEV. After incubating for 24 hours in the presence of the inhibitor, infected wells were
482 scored and the TCID₅₀ calculated.

483 **CRISPR/Cas 9 targeting of mmu-miR-673**

484 To create a cell line lacking mmu-mmiR-673-5p, the Alt-R® CRISPR-Cas9 System (IDT) was
485 used. Two different crRNAs were designed to target sequences within the pri-miRNA sequence
486 hairpin to induce structural changes disrupting processing by the Microprocessor and Dicer.
487 Cas9 protein and tracrRNAs were transfected with the Neon® Transfection System followed
488 by cell sorting to create single cell clones. Genomic DNA was purified and screened by PCR
489 followed by restriction site disruption analyses for the pri-miRNA sequence. Genomic DNA
490 of the pri-miRNA sequence of candidates was amplified using primers in **Table S1**, and cloned
491 into pGEMt-easy vector for sequencing.

492 **miRNA qRT-PCR**

493 Total RNA (100ng) was used to quantify mmu-mmiR-673-5p levels. RNA was first converted
494 to cDNA using miRCURY LNA RT kit (Qiagen). cDNA was diluted 1/25 for RT-qPCR using
495 miRCURY LNA SYBR Green kit and amplified using mmu-mmiR-673-5p specific primers
496 (Qiagen) and U6 as a loading control. Quantitative PCR was carried out on a Roche LC480
497 light cycler and analysed using the second derivative method.

498 **Data availability**

499 All processed Mass spectrometry data is provided as a Supplementary Excel File, including
500 LFQ intensity values for each protein detected in each of the samples. All raw data are available
501 from corresponding author upon request.

502 **Acknowledgments**

503 We thank our colleagues at the Institute of Immunology and Infection Research for advice and
504 discussions. We thank J.F. Caceres, H. Marks, R. Zamoyska and Y. Crow for critical reading
505 of the manuscript, and R. Blleloch, P. Digard, E. Gaunt and R. Zamoyska labs for reagents. We
506 thank Jimi Wills from the IGMM Mass spectrometry facility for analysis of protein samples.
507 This work is supported by the Wellcome Trust (107665/Z/15/Z), L.K is supported by a MRC-
508 DTP in Precision Medicine Fellowship.

509 **Author Contributions**

510 J.W. and S.M. conceived and designed the study. J.W. and L.K. conducted all the experiments.
511 The manuscript was co-written by all authors.

512 **Competing interests**

513 The authors declare no competing interests

514

515

516

517

518

519 **Figure Legends**

520 **Figure 1. ESCs lack IFN response and are more susceptible to viral infection**

521 **(a)** Quantification of *ifnb1* expression in ESCs and the somatic mouse cell lines NIH3T3 and
522 BV-2 after transfection with the dsRNA analogue poly(I:C). Data show the average (n=3) +/-
523 s.e.m, (*) p-value <0.05 by t-test. **(b)** Quantification of *ifnb1* expression after activation of the
524 cGAS response by Y-DNA (G3-YSD) in the same cells lines as **(a)**. Data show the average
525 (n=3, except for ESC2, n=2) +/- s.e.m, (*) p-value <0.05 by t-test. **(c)** Susceptibility
526 (TCID₅₀/ml) of same cell lines as used in **(a)** to TMEV infection. **(d)** Quantification of *ifnb1*
527 expression in pluripotent and differentiated ESCs after activation with poly(I:C). Data show
528 the average (n=3) fold change over mock treated cells, +/- s.d. (*) p-value <0.05 by t-test.

529

530 **Figure 2. MiRNAs regulate IFN response.**

531 **(a)** Susceptibility (TCID₅₀/ml) of miRNA deficient cells (*Dgcr8*^{-/-}, *Dicer*^{-/-}) and wild-type
532 parental cells (*Dgcr8*^{+/+}(ESC1), *Dicer*^{+/+}(ESC2)) to TMEV infection, higher values represent
533 higher susceptibility (n=4, p-value <0.05, t-test). **(b)** Quantification of Influenza A replication
534 after infection of the same cell lines as in **(a)**, data show the average (n=3) +/- s.d. (*) p-value
535 <0.05 by t-test. **(c, d)** Quantification of *Ifnb1* expression of ESCs lacking *Dgcr8* **(c)** or *Dicer*
536 **(d)** to stimulation with poly(I:C) and Y-DNA. Data show average (n=3) +/- s.d., normalized to
537 mock, (*) p-value <0.05 by t-test. **(e, f)** Quantification of TMEV replication after infection in
538 *Dgcr8* **(e)** and *Dicer* **(f)** parental (+/+), deficient (-/-) and rescued (resc) cell lines. Data are
539 normalized to miRNA deficient cell lines susceptibility. Data show average (n=3) +/- s.d (*)
540 p-value <0.05 by t-test. Northern blots for three stem-cell specific miRNAs, as control for
541 knock-out and rescue of *Dgcr8* and *Dicer*, are shown at the right of each panel.

542

543 **Figure 3. MAVS is downregulated by miRNAs in ESCs**

544 (a) Susceptibility of *Dgcr8*^{-/-}, *Dicer*^{-/-} and parental cells to TMEV infection after inhibition of
545 IRF3 (BX795) and Nf-κB (BMS345541), normalized to mock-treated cells. (b) Heat map of
546 significantly differentially expressed proteins (p<0.05) in the absence (*Dgcr8*^{-/-}) or presence
547 (*Dgcr8*^{resc}) of miRNAs identified by STRING analysis. (c) Western blot analysis of MAVS
548 expression in miRNA-deficient cells (*Dgcr8*^{-/-} and *Dicer*^{-/-}, lanes 2 and 5), wild-type
549 counterparts (*Dgcr8*^{+/+} and *Dicer*^{+/+}, lanes 1 and 4) and respective rescued ESCs lines
550 (*Dgcr8*^{resc} and *Dicer*^{resc}, lanes 3 and 6). MAVS quantification normalized to Tubulin and
551 relative to wild-type levels is shown at the top of the panel.

552

553 **Figure 4. ESCs regain *Ifnb1* expression after MAVS overexpression**

554 (a) Dual luciferase assay with MAVS, RIG-I and MDA5 3'UTRs in miRNA deficient cells
555 lines (*Dgcr8*^{-/-} and *Dicer*^{-/-}). Data show the average (n=3) +/- s.d normalized to Renilla and
556 relative to the parental lines, (*) p-value <0.05 by t-test (b) Western blot of cell line
557 overexpressing MAVS lacking the 3'UTR in *Dgcr8*^{+/+} cells (lane 3). MAVS quantification
558 normalized to Tubulin and relative to wild-type is shown at the top (c) Susceptibility
559 (TCID₅₀/ml) of same cells lines as in (b) to TMEV infection (left panel) and quantification of
560 viral RNA after TMEV infections in the same cell lines (right panel). Data show the average
561 (n=5) +/- s.d. (*) p-value <0.05 by t-test (d) *Ifnb* mRNA expression after poly(I:C) transfection
562 of the same cell lines as in (b), average is represented (n=3) +/- s.d, normalized to *Dgcr8*^{+/+}
563 cell line, (*) p-value <0.05 by t-test.

564

565 **Figure 5. MiR-673-5p regulates MAVS**

566 (a) Transfection of miRNA mimics miR-125a-5p, miR-125b-5p, miR-185-5p and miR-673-5p
567 in *Dgcr8*^{-/-} cells followed by MAVS western blot. MAVS quantification normalized to Tubulin
568 and relative to wild-type is shown at the top (b) Quantification of TMEV replication by qRT-
569 PCR in the same cell lines as in (a) (n=3). (c) MAVS western blot analysis of *Dgcr8*^{+/+} cells
570 transfected with antagomirs against miR-125a-5p, miR-125b-5p and miR-673-5p. MAVS
571 quantification normalized to Tubulin and relative to wild-type is shown at the top. (d)
572 Quantification of mir-673 expression in CRISPR knock out cell lines. (e) Western blot analysis
573 of MAVS expression in *miR-673*^{-/-} cell lines. MAVS quantification normalized to Tubulin and
574 relative to wild-type is shown at the top (f) Quantification of TMEV replication in miR-673
575 CRISPR knock-out cell lines in a *Dgcr8*^{+/+} background. Data show the average (n=3) +/- s.d
576 (*) p-value <0.05 by t-test.

577

578 **Extended Data**

579 Supplementary Figures 1 to 6.

580 Table S1 (oligonucleotides)

581 Supplementary Excel file (mass spectrometry results)

582

583

584

585

586

587

588

589 **References**

- 590 Aguado, L. C., Schmid, S., Sachs, D., Shim, J. V., Lim, J. K. and TenOever, B. R. (2015)
591 ‘microRNA Function Is Limited to Cytokine Control in the Acute Response to Virus
592 Infection’, *Cell Host & Microbe*. Elsevier Inc., 18(6), pp. 714–722. doi:
593 10.1016/j.chom.2015.11.003.
- 594 Ahmad, S., Mu, X., Yang, F., Greenwald, E., Park, J. W., Jacob, E., Zhang, C. Z. and Hur, S.
595 (2018) ‘Breaching Self-Tolerance to Alu Duplex RNA Underlies MDA5-Mediated
596 Inflammation’, *Cell*. Elsevier Inc., 172(4), p. 797–810.e13. doi: 10.1016/j.cell.2017.12.016.
- 597 Bekisz, J., Baron, S., Balinsky, C., Morrow, A. and Zoon, K. C. (2010) ‘Antiproliferative
598 Properties of Type I and Type II Interferon.’, *Pharmaceuticals (Basel, Switzerland)*.
599 Multidisciplinary Digital Publishing Institute (MDPI), 3(4), pp. 994–1015. doi:
600 10.3390/ph3040994.
- 601 Bernstein, E., Caudy, A. A., Hammond, S. M. and Hannon, G. J. (2001) ‘Role for bidentate
602 ribnuclease in the initiation site of RNA interference’, *Nature*, 409(1997), pp. 363–366.
- 603 Bogerd, H. P., Skalsky, R. L., Kennedy, E. M., Furuse, Y., Whisnant, A. W., Flores, O.,
604 Schultz, K. L. W., Putnam, N., Barrows, N. J., Sherry, B., Scholle, F., Garcia-Blanco, M. A.,
605 Griffin, D. E. and Cullen, B. R. (2014) ‘Replication of Many Human Viruses Is Refractory to
606 Inhibition by Endogenous Cellular MicroRNAs’, *Journal of Virology*, 88(14), pp. 8065–
607 8076. doi: 10.1128/JVI.00985-14.
- 608 Borden, E. C., Hogan, T. F. and Voelkel, J. G. (1982) ‘Comparative antiproliferative activity
609 in vitro of natural interferons alpha and beta for diploid and transformed human cells.’,
610 *Cancer research*, 42(12), pp. 4948–53.
- 611 Bracci, L., Sistigu, A., Proietti, E. and Moschella, F. (2017) ‘The added value of type I
612 interferons to cytotoxic treatments of cancer’, *Cytokine & Growth Factor Reviews*, 36, pp.
613 89–97. doi: 10.1016/j.cytogfr.2017.06.008.
- 614 Burke, D. C., Graham, C. F. and Lehman, J. M. (1978) Appearance of Interferon Inducibility
615 and Sensitivity during Differentiation of Murine Teratocarcinoma Cells in Vitro, *Cell*, 13, pp.
616 243-9.

- 617 Chan, Y. K. and Gack, M. U. (2016) ‘Viral evasion of intracellular DNA and RNA sensing’,
618 *Nature Reviews Microbiology*. Nature Publishing Group, 14(6), pp. 360–373. doi:
619 10.1038/nrmicro.2016.45.
- 620 Chen, G.-Y., Hwang, S.-M., Su, H.-J., Kuo, C.-Y., Luo, W.-Y., Lo, K.-W., Huang, C.-C.,
621 Chen, C.-L., Yu, S.-H. and Hu, Y.-C. (2012) ‘Defective Antiviral Responses of Induced
622 Pluripotent Stem Cells to Baculoviral Vector Transduction’. doi: 10.1128/JVI.00808-12.
- 623 Chen, L.-L., Yang, L. and Carmichael, G. (2010) ‘Molecular basis for an attenuated
624 cytoplasmic dsRNA response in human embryonic stem cells’, *Cell Cycle*, 9(17), pp. 3552–
625 3564. doi: 10.4161/cc.9.17.12792.
- 626 Cheng, W.-Y., He, X.-B., Jia, H.-J., Chen, G.-H., Jin, Q.-W., Long, Z.-L. and Jing, Z.-Z.
627 (2018) ‘The cGas–Sting Signaling Pathway Is Required for the Innate Immune Response
628 Against Ectromelia Virus’, *Frontiers in Immunology*. Frontiers, 9, p. 1297. doi:
629 10.3389/fimmu.2018.01297.
- 630 Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A.,
631 Rote, N. S., Cope, L. M., Snyder, A., Makarov, V., Buhu, S., Slamon, D. J., Wolchok, J. D.,
632 Pardoll, D. M., Beckmann, M. W., Zahnow, C. A., Merghoub, T., Chan, T. A., Baylin, S. B.
633 and Strick, R. (2015) ‘Inhibiting DNA Methylation Causes an Interferon Response in Cancer
634 via dsRNA Including Endogenous Retroviruses’, *Cell*, 162(5), pp. 974–986. doi:
635 10.1016/j.cell.2015.07.011.
- 636 D’Angelo, W., Acharya, D., Wang, R., Wang, J., Gurung, C., Chen, B., Bai, F. and Guo, Y.-
637 L. (2016) ‘Development of Antiviral Innate Immunity During In Vitro Differentiation of
638 Mouse Embryonic Stem Cells’, *Stem Cells and Development*, 25(8), pp. 648–659. doi:
639 10.1089/scd.2015.0377.
- 640 Delorme-Axford, E., Sadovsky, Y. and Coyne, C. B. (2014) ‘The Placenta as a Barrier to
641 Viral Infections’, *Annual Review of Virology*, 1(1), pp. 133–146. doi: 10.1146/annurev-
642 virology-031413-085524.
- 643 Gregory, R. I., Yan, K.-P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N. and
644 Shiekhattar, R. (2004) ‘The Microprocessor complex mediates the genesis of microRNAs.’,
645 *Nature*, 432, pp. 235–240. doi: 10.1038/nature03120.

- 646 Greve, T. S., Judson, R. L. and Blelloch, R. (2013) ‘microRNA Control of Mouse and Human
647 Pluripotent Stem Cell Behavior’, *Annual Review of Cell and Developmental Biology*, 29(1),
648 pp. 213–239. doi: 10.1146/annurev-cellbio-101512-122343.
- 649 Grow, E. J., Flynn, R. A., Chavez, S. L., Bayless, N. L., Wossidlo, M., Wesche, D., Martin,
650 L., Ware, C., Blish, C. A., Chang, H. Y., Pera, R. A. R. and Wysocka, J. (2015) ‘Intrinsic
651 retroviral reactivation in human preimplantation embryos and pluripotent cells HHS Public
652 Access’, *Nature*, 522(7555), pp. 221–225. doi: 10.1038/nature14308.
- 653 Guo, Y.-L., Carmichael, G. G., Wang, R., Hong, X., Acharya, D., Huang, F. and Bai, F.
654 (2015) ‘Attenuated Innate Immunity in Embryonic Stem Cells and Its Implications in
655 Developmental Biology and Regenerative Medicine’, *STEM CELLS*. John Wiley & Sons,
656 Ltd, 33(11), pp. 3165–3173. doi: 10.1002/stem.2079.
- 657 Hertzog, P. J., Hwang, S. Y. and Kola, I. (1994) ‘Role of interferons in the regulation of cell
658 proliferation, differentiation, and development.’, *Mol. Reprod.*, 39, pp. 226–32. doi:
659 10.1002/mrd.1080390216.
- 660 Herzner, A.-M., Hagmann, C. A., Goldeck, M., Wolter, S., Kübler, K., Wittmann, S.,
661 Gramberg, T., Andreeva, L., Hopfner, K.-P., Mertens, C., Zillinger, T., Jin, T., Xiao, T. S.,
662 Bartok, E., Coch, C., Ackermann, D., Hornung, V., Ludwig, J., Barchet, W., Hartmann, G.
663 and Schlee, M. (2015) ‘Sequence-specific activation of the DNA sensor cGAS by Y-form
664 DNA structures as found in primary HIV-1 cDNA’, *Nature Immunology*. Nature Publishing
665 Group, 16(10), pp. 1025–1033. doi: 10.1038/ni.3267.
- 666 Hong, X.-X. and Carmichael, G. G. (2013) ‘Innate Immunity in Pluripotent Human Cells’,
667 *Journal of Biological Chemistry*, 288(22), pp. 16196–16205. doi: 10.1074/jbc.M112.435461.
- 668 Hsu, A. C.-Y., Dua, K., Starkey, M. R., Haw, T.-J., Nair, P. M., Nichol, K., Zammit, N.,
669 Grey, S. T., Baines, K. J., Foster, P. S., Hansbro, P. M. and Wark, P. A. (2017) ‘MicroRNA-
670 125a and -b inhibit A20 and MAVS to promote inflammation and impair antiviral response in
671 COPD.’, *JCI insight*, 2(7), p. e90443. doi: 10.1172/jci.insight.90443.
- 672 Irudayam, J. I., Contreras, D., Spurka, L., Subramanian, A., Allen, J., Ren, S., Kanagavel, V.,
673 Nguyen, Q., Ramaiah, A., Ramamoorthy, K., French, S. W., Klein, A. S., Funari, V. and
674 Arumugaswami, V. (2015) ‘Characterization of type I interferon pathway during hepatic

- 675 differentiation of human pluripotent stem cells and hepatitis C virus infection.’, *Stem cell*
676 *research*. NIH Public Access, 15(2), pp. 354–364. doi: 10.1016/j.scr.2015.08.003.
- 677 Ivashkiv, L. B. and Donlin, L. T. (2015) ‘Regulation of type I interferon responses’, *Nature*
678 *Reviews Immunology*, 14(1), pp. 36–49. doi: 10.1038/nri3581.Regulation.
- 679 Kanellopoulou, C., Muljo, S. A., Kung, A. L., Ganesan, S., Drapkin, R., Jenuwein, T.,
680 Livingston, D. M. and Rajewsky, K. (2005) ‘Dicer-deficient mouse embryonic stem cells are
681 defective in differentiation and centromeric silencing’, *Genes and Development*, 19(4), pp.
682 489–501. doi: 10.1101/gad.1248505.
- 683 Kawai, T., Takahashi, K., Sato, S., Coban, C., Kumar, H., Kato, H., Ishii, K. J., Takeuchi, O.
684 and Akira, S. (2005) ‘IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I
685 interferon induction’, *Nature Immunology*, 6(10), pp. 981–988. doi: 10.1038/ni1243.
- 686 Lawrence, T. (2009) ‘The Nuclear Factor NF- B Pathway in Inflammation’, *Cold Spring*
687 *Harbor Perspectives in Biology*, 1(6), pp. a001651–a001651. doi:
688 10.1101/cshperspect.a001651.
- 689 Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., Lee, J., Provost, P., Rådmark, O., Kim,
690 S. and Kim, V. N. (2003) ‘The nuclear RNase III Drosha initiates microRNA processing’,
691 *Nature*, 425(6956), pp. 415–419. doi: 10.1038/nature01957.
- 692 Li, Y., Basavappa, M., Lu, J., Dong, S., Cronkite, D. A., Prior, J. T., Reinecker, H.-C.,
693 Hertzog, P., Han, Y., Li, W.-X., Cheloufi, S., Karginov, F. V., Ding, S.-W. and Jeffrey, K. L.
694 (2016) ‘Induction and suppression of antiviral RNA interference by influenza A virus in
695 mammalian cells.’, *Nature microbiology*, 2, p. 16250. doi: 10.1038/nmicrobiol.2016.250.
- 696 Macfarlan, T. S., Gifford, W. D., Driscoll, S., Lettieri, K., Rowe, H. M., Bonanomi, D., Firth,
697 A., Singer, O., Trono, D. and Pfaff, S. L. (2012) ‘Embryonic stem cell potency fluctuates
698 with endogenous retrovirus activity’, *Nature*. Nature Publishing Group, 487(7405), pp. 57–
699 63. doi: 10.1038/nature11244.
- 700 Macia, A., Blanco-Jimenez, E. and García-Pérez, J. L. (2015) ‘Retrotransposons in
701 pluripotent cells: Impact and new roles in cellular plasticity’, *Biochimica et Biophysica Acta*
702 *(BBA) - Gene Regulatory Mechanisms*. Elsevier, 1849(4), pp. 417–426. doi:
703 10.1016/J.BBAGRM.2014.07.007.

- 704 Macias, S., Plass, M., Stajuda, A., Michlewski, G., Eyraes, E. and Cáceres, J. F. (2012)
705 ‘DGCR8 HITS-CLIP reveals novel functions for the Microprocessor’, *Nature Structural &*
706 *Molecular Biology*, pp. 760–766.
- 707 Maillard, P. V., Ciaudo, C., Marchais, A., Li, Y., Jay, F., Ding, S. W. and Voinnet, O. (2013)
708 ‘Antiviral RNA interference in mammalian cells.’, *Science (New York, N.Y.)*, 342, pp. 235–8.
709 doi: 10.1126/science.1241930.
- 710 Maillard, P. V, Van der Veen, A. G., Deddouche-Grass, S., Rogers, N. C., Merits, A. and
711 Reis Sousa, C. (2016) ‘Inactivation of the type I interferon pathway reveals long double-
712 stranded RNA-mediated RNA interference in mammalian cells’, *The EMBO Journal*, 35, pp.
713 2505–2518. doi: 10.15252/embj.
- 714 McFadden, M. J., Gokhale, N. S. and Horner, S. M. (2017) ‘Protect this house: cytosolic
715 sensing of viruses’, *Current Opinion in Virology*. Elsevier, 22, pp. 36–43. doi:
716 10.1016/J.COVIRO.2016.11.012.
- 717 Papadopoulou, A. S., Dooley, J., Linterman, M. A., Pierson, W., Ucar, O., Kyewski, B.,
718 Zuklys, S., Hollander, G. A., Matthys, P., Gray, D. H. D., De Strooper, B. and Liston, A.
719 (2012) ‘The thymic epithelial microRNA network elevates the threshold for infection-
720 associated thymic involution via miR-29a mediated suppression of the IFN- α receptor’,
721 *Nature Immunology*, 13(2), pp. 181–187. doi: 10.1038/ni.2193.
- 722 Peaston, A. E., Evsikov, A. V, Graber, J. H., De Vries, W. N., Holbrook, A. E., Solter, D. and
723 Knowles, B. B. (2004) ‘Retrotransposons Regulate Host Genes in Mouse Oocytes and
724 Preimplantation Embryos’, *Developmental Cell*, 7 (4), pp. 597-606.
- 725 Rice, G. I., del Toro Duany, Y., Jenkinson, E. M., Forte, G. M. a, Anderson, B. H., Ariaudo,
726 G., Bader-Meunier, B., Baidam, E. M., Battini, R., Beresford, M. W., Casarano, M.,
727 Chouchane, M., Cimaz, R., Collins, A. E., Cordeiro, N. J. V, Dale, R. C., Davidson, J. E., De
728 Waele, L., Desguerre, I., Faivre, L., Fazzi, E., Isidor, B., Lagae, L., Latchman, A. R., Lebon,
729 P., Li, C., Livingston, J. H., Lourenço, C. M., Mancardi, M. M., Masurel-Paulet, A.,
730 McInnes, I. B., Menezes, M. P., Mignot, C., O’Sullivan, J., Orcesi, S., Picco, P. P., Riva, E.,
731 Robinson, R. a, Rodriguez, D., Salvatici, E., Scott, C., Szybowska, M., Tolmie, J. L.,
732 Vanderver, A., Vanhulle, C., Vieira, J. P., Webb, K., Whitney, R. N., Williams, S. G., Wolfe,
733 L. a, Zuberi, S. M., Hur, S. and Crow, Y. J. (2014) ‘Gain-of-function mutations in IFIH1

- 734 cause a spectrum of human disease phenotypes associated with upregulated type I interferon
735 signaling.’, *Nature Genetics*, 46(5), pp. 503–9. doi: 10.1038/ng.2933.
- 736 Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang,
737 G., Jones, P. A., Pugh, T. J., O’Brien, C. and De Carvalho, D. D. (2015) ‘DNA-
738 Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by
739 Endogenous Transcripts’, *Cell*, 162(5), pp. 961–973. doi: 10.1016/j.cell.2015.07.056.
- 740 Scaduto, R. C. and Grotyohann, L. W. (1999) ‘Measurement of mitochondrial membrane
741 potential using fluorescent rhodamine derivatives’, *Biophysical Journal*. Elsevier, 76(1 I), pp.
742 469–477. doi: 10.1016/S0006-3495(99)77214-0.
- 743 Schafer, S. L., Lin, R., Moore, P. a, Hiscott, J. and Pitha, P. M. (1998) ‘Regulation of type I
744 interferon gene expression by interferon regulatory factor-3.’, *The Journal of biological*
745 *chemistry*, 273(5), pp. 2714–20. doi: 10.1074/JBC.273.5.2714.
- 746 Treiber, T., Treiber, N. and Meister, G. (2018) ‘Regulation of microRNA biogenesis and its
747 crosstalk with other cellular pathways’, *Nature Reviews Molecular Cell Biology*. Nature
748 Publishing Group, p. 1. doi: 10.1038/s41580-018-0059-1.
- 749 Tsai, K., Courtney, D. G., Kennedy, E. M. and Cullen, B. R. (2018) ‘Influenza A virus-
750 derived siRNAs increase in the absence of NS1 yet fail to inhibit virus replication’, *RNA*, p.
751 rna.066332.118. doi: 10.1261/rna.066332.118.
- 752 van der Veen, A. G., Maillard, P. V, Schmidt, J. M., Lee, S. A., Deddouche-Grass, S., Borg,
753 A., Kjær, S., Snijders, A. P. and Reis e Sousa, C. (2018) ‘The RIG-I-like receptor LGP2
754 inhibits Dicer-dependent processing of long double-stranded RNA and blocks RNA
755 interference in mammalian cells’, *The EMBO Journal*, 37(4), p. e97479. doi:
756 10.15252/embj.201797479.
- 757 Wan, S., Ashraf, U., Ye, J., Duan, X., Zohaib, A., Wang, W., Chen, Z., Zhu, B., Li, Y., Chen,
758 H. and Cao, S. (2016) ‘MicroRNA-22 negatively regulates poly(I:C)-triggered type I
759 interferon and inflammatory cytokine production via targeting mitochondrial antiviral
760 signaling protein (MAVS)’, *Oncotarget*, 7(47). doi: 10.18632/oncotarget.12395.
- 761 Wang, R., Wang, J., Acharya, D., Paul, A. M., Bai, F., Huang, F. and Guo, Y.-L. (2014)
762 ‘Antiviral Responses in Mouse Embryonic Stem Cells’, *Journal of Biological Chemistry*,

- 763 289(36), pp. 25186–25198. doi: 10.1074/jbc.M113.537746.
- 764 Wang, R., Wang, J., Paul, A. M., Acharya, D., Bai, F., Huang, F. and Guo, Y.-L. (2013)
765 ‘Mouse Embryonic Stem Cells Are Deficient in Type I Interferon Expression in Response to
766 Viral Infections and Double-stranded RNA’, *Journal of Biological Chemistry*, 288(22), pp.
767 15926–15936. doi: 10.1074/jbc.M112.421438.
- 768 Wang, Y., Medvid, R., Melton, C., Jaenisch, R. and Blelloch, R. (2007) ‘DGCR8 is essential
769 for microRNA biogenesis and silencing of embryonic stem cell self-renewal’, *Nature*
770 *Genetics*, 39(3), pp. 380–385. doi: 10.1038/ng1969.
- 771 Witteveldt, J., Ivens, A. and Macias, S. (2018) ‘Inhibition of Microprocessor Function during
772 the Activation of the Type I Interferon Response’, *Cell Reports*, 23(11), pp. 3275–3285. doi:
773 10.1016/j.celrep.2018.05.049.
- 774 Wu, X., Dao Thi, V. L., Huang, Y., Billerbeck, E., Saha, D., Hoffmann, H.-H., Wang, Y.,
775 Silva, L. A. V., Sarbanes, S., Sun, T., Andrus, L., Yu, Y., Quirk, C., Li, M., MacDonald, M.
776 R., Schneider, W. M., An, X., Rosenberg, B. R. and Rice, C. M. (2018) ‘Intrinsic Immunity
777 Shapes Viral Resistance of Stem Cells’, *Cell*, 172(3), p. 423–438.e25. doi:
778 10.1016/j.cell.2017.11.018.
- 779 Wu, X., Robotham, J. M., Lee, E., Dalton, S., Kneteman, N. M., Gilbert, D. M. and Tang, H.
780 (2012) ‘Productive Hepatitis C Virus Infection of Stem Cell-Derived Hepatocytes Reveals a
781 Critical Transition to Viral Permissiveness during Differentiation’, *PLoS Pathogens*. Edited
782 by G. G. Luo, 8(4), p. e1002617. doi: 10.1371/journal.ppat.1002617.
- 783 Yin, Y., Zhou, L. and Yuan, S. (2018) ‘Enigma of Retrotransposon Biology in Mammalian
784 Early Embryos and Embryonic Stem Cells’, *Stem Cells International*. Hindawi, 2018, pp. 1–
785 6. doi: 10.1155/2018/6239245.
- 786

Figure 1




Figure 2




Figure 3






Figure 4


A



B



C



D




Figure 5

